Clinica Universidad de Navarra
Pamplona, Navarre, Spain
56 recruiting
Showing 1–20 of 49 trials
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 1Phase 2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
Regeneron Pharmaceuticals149 enrolled32 locationsNCT05828511
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company440 enrolled138 locationsNCT06615479
Recruiting
Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company187 enrolled19 locationsNCT06153251
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled383 locationsNCT05253651
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Solid Tumor
Eisai Inc.182 enrolled58 locationsNCT04300556
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled157 locationsNCT07011732
Recruiting
Phase 2
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Ovarian CancerPeritoneal Carcinomatosis
Oncoinvent Solutions AS114 enrolled10 locationsNCT06504147
Recruiting
Phase 3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma ( FL)
Regeneron Pharmaceuticals822 enrolled190 locationsNCT06091254
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Non-small Cell Lung Cancer (NSCLC)KRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more
Revolution Medicines, Inc.616 enrolled89 locationsNCT06162221
Recruiting
Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Phase 1
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer
Amgen479 enrolled56 locationsNCT04221542
Recruiting
Phase 1Phase 2
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
B Cell Precursor Acute Lymphoblastic Leukemia
Amgen281 enrolled86 locationsNCT04521231
Recruiting
Phase 1Phase 2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb308 enrolled35 locationsNCT06090539
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Alzheimer s Disease
Bristol-Myers Squibb586 enrolled111 locationsNCT06976216
Recruiting
Phase 3
A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy
Multiple Myeloma
Pfizer1,116 enrolled88 locationsNCT05623020
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation
Relay Therapeutics, Inc.540 enrolled76 locationsNCT06982521
Recruiting
Not Applicable
WATCHMAN FLX Pro European Registry
Left Atrial Appendage ClosureNon-valvular Atrial Fibrillation (AF)
Boston Scientific Corporation1,000 enrolled3 locationsNCT07262255
Recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loxo Oncology, Inc.249 enrolled133 locationsNCT06588478
Recruiting
Not Applicable
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
Atrial Fibrillation (AF)Persistant Atrial Fibrillation
Boston Scientific Corporation699 enrolled37 locationsNCT07187115